Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma | Zendy

Christudas Morais | Zendy; Helen Healy | Zendy; David W. Johnson | Zendy; Glenda C. Gobé | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma

Author(s) -

Christudas Morais,

Helen Healy,

David W. Johnson,

Glenda C. Gobé

Publication year - 2009

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfp673

Subject(s) - pyrrolidine dithiocarbamate , medicine , cancer research , renal cell carcinoma , apoptosis , nfkb1 , relb , cancer , pathology , transcription factor , nf κb , immunology , biology , inflammation , biochemistry , gene

Renal cell carcinoma (RCC) is a highly metastatic and lethal disease with few efficacious treatments. Many studies have shown that the ubiquitous transcription factor nuclear factor kappa B (NF-kappaB) plays a key role in the development and progression of many cancers including RCC. The aim of this investigation was to evaluate the anti-cancer effect of pyrrolidine dithiocarbamate (PDTC), a NF-kappaB inhibitor, in a murine xenograft model of RCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research